Crinetics Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Crinetics Pharmaceuticals, Inc.
While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.
Chiasma has bounced back from a 2016 CRL for Mycapssa with a new SPA-agreed Phase III trial meeting all its primary and secondary endpoints. The product is positioned to be the first oral treatment for acromegaly.
Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.
With biopharma venture capital investment of $9.67bn during the first half, 2018's total is on track to beat 2017 in the third quarter. IPOs, one of the factors fueling VC investment, continue to boom with five more drug developers slated to go public this week.
- Drug Discovery Tools